Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- 25 March 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (3) , 590-597
Abstract
Background: Interleukin 4 (IL-4), increased in tuberculosis infection, may impair bacterial killing. Blocking IL-4 confers benefit in animal models. We evaluated safety and efficacy of pascolizumab (humanized anti–IL-4 monoclonal antibody) as adjunctive tuberculosis treatment. Methods: Participants with rifampicin-susceptible pulmonary tuberculosis received a single intravenous infusion of pascolizumab or placebo, and standard 6-month tuberculosis treatment. Pascolizumab dose increased in successive cohorts: (1) nonrandomized 0.05 mg/kg (n = 4); (2) nonrandomized 0.5 mg/kg (n = 4); (3) randomized 2.5 mg/kg (n = 9) or placebo (n = 3); and (4) randomized 10 mg/kg (n = 9) or placebo (n = 3). Coprimary safety outcome was study-drug–related grade 4 or serious adverse event (G4/SAE) in all cohorts (1–4). Coprimary efficacy outcome was week 8 sputum culture time-to-positivity (TTP) in randomized cohorts (3–4) combined. Results: Pascolizumab levels exceeded IL-4 50% neutralizing dose for 8 weeks in 78%–100% of participants in cohorts 3–4. There were no study-drug–related G4/SAEs. Median week-8 TTP was 42 days in pascolizumab and placebo groups (P = .185). Rate of TTP increase was greater with pascolizumab (difference from placebo 0.011 log10 TTP/day; 95% Bayesian credible interval 0.006 to 0.015 log10 TTP/day). Conclusions: There was no evidence to suggest blocking IL-4 was unsafe. Preliminary efficacy findings are consistent with animal models. This supports further investigation of adjunctive anti–IL-4 interventions for tuberculosis in larger phase 2 trials. Clinical Trials Registration: NCT 01638520.Keywords
Funding Information
- Singapore Ministry of Health (NMRC/CIRG/1322/2012)
- GSK
This publication has 15 references indexed in Scilit:
- Application of Bayesian approaches in drug development: starting a virtuous cycleNature Reviews Drug Discovery, 2023
- Anti-tuberculosis treatment strategies and drug development: challenges and prioritiesNature Reviews Microbiology, 2022
- Multimodal profiling of lung granulomas in macaques reveals cellular correlates of tuberculosis controlImmunity, 2022
- Therapeutic host-directed strategies to improve outcome in tuberculosisMucosal Immunology, 2019
- Robust Bayesian nonlinear mixed‐effects modeling of time to positivity in tuberculosis trialsPharmaceutical Statistics, 2018
- Robust fit of Bayesian mixed effects regression models with application to colony forming unit count in tuberculosis researchStatistics in Medicine, 2017
- Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trialThe Lancet, 2016
- Dupilumab in Persistent Asthma with Elevated Eosinophil LevelsNew England Journal of Medicine, 2013
- Beneficial effect of anti-interleukin-4 antibody when administered in a murine model of tuberculosis infectionTuberculosis, 2008
- Pulmonary tuberculosis in BALB/c mice with non‐functional IL‐4 genes: changes in the inflammatory effects of TNF‐α and in the regulation of fibrosisEuropean Journal of Immunology, 2003